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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Through a mult sector approach, the DREAMS Partnership aimed to reduce HIV incidence
among adolescent girls and young women (AGYW) by 40% over 2 years in high-burden dis-
tricts across sub-Saharan Africa. DREAMS promotes a combination package of evidence-
based interventions to reduce individual, family, partner, and community-based drivers of
young women’s heightened HIV risk. We evaluated the impact of DREAMS on HIV inci-
dence among AGYW and young men in 2 settings.
Methods and findings
We directly estimated HIV incidence rates among open population-based cohorts participat-
ing in demographic and HIV serological surveys from 2006 to 2018 annually in uMkhanya-
kude (KwaZulu-Natal, South Africa) and over 6 rounds from 2010 to 2019 in Gem (Siaya,
Kenya). We compared HIV incidence among AGYW aged 15 to 24 years before DREAMS
and up to 3 years after DREAMS implementation began in 2016. We investigated the timing
of any change in HIV incidence and whether the rate of any change accelerated during
DREAMS implementation. Comparable analyses were also conducted for young men (20 to
29/34 years).
In uMkhanyakude, between 5,000 and 6,000 AGYW were eligible for the serological sur-
vey each year, an average of 85% were contacted, and consent rates varied from 37% to
67%. During 26,395 person-years (py), HIV incidence was lower during DREAMS implemen-
tation (2016 to 2018) than in the previous 5-year period among 15- to 19-year-old females
(4.5 new infections per 100 py as compared with 2.8; age-adjusted rate ratio (aRR) = 0.62,
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95% confidence interval [CI] 0.48 to 0.82), and lower among 20- to 24-year-olds (7.1/100 py
as compared with 5.8; aRR = 0.82, 95% CI 0.65 to 1.04). Declines preceded DREAMS intro-
duction, beginning from 2012 to 2013 among the younger and 2014 for the older women, with
no evidence of more rapid decline during DREAMS implementation. In Gem, between 8,515
and 11,428 AGYW were eligible each survey round, an average of 34% were contacted and
offered an HIV test, and consent rates ranged from 84% to 99%. During 10,382 py, declines
in HIV incidence among 15- to 19-year-olds began before DREAMS and did not change after
DREAMS introduction. Among 20- to 24-year-olds in Gem, HIV incidence estimates were
lower during DREAMS implementation (0.64/100 py) compared with the pre-DREAMS period
(0.94/100 py), with no statistical evidence of a decline (aRR = 0.69, 95% CI 0.53 to 2.18).
Among young men, declines in HIV incidence were greater than those observed among
AGYW and also began prior to DREAMS investments. Study limitations include low study
power in Kenya and the introduction of other interventions such as universal treatment for
HIV during the study period.
Conclusions
Substantial declines in HIV incidence among AGYW were observed, but most began before
DREAMS introduction and did not accelerate in the first 3 years of DREAMS implementa-
tion. Like the declines observed among young men, they are likely driven by earlier and
ongoing investments in HIV testing and treatment. Longer-term implementation and evalua-
tion are needed to assess the impact of such a complex HIV prevention intervention and to
help accelerate reductions in HIV incidence among young women.
Author summary
Why was this study done?
• Adolescent girls and young women (AGYW) experience high risk of HIV infection rela-
tive to other demographic groups, and evidence is needed to drive down the rate of new
infections.
• DREAMS is a large investment in combination HIV prevention for AGYW in 15 coun-
tries, and evidence of its effectiveness can guide ongoing efforts to achieve epidemic
control and Sustainable Development Goal 3 to end AIDS as a public health threat by
2030.
What did the researchers do and find?
• With large open cohorts of AGYW and young men resident in demographic surveil-
lance sites in western Kenya and KwaZulu Natal, South Africa, we compared HIV inci-
dence before DREAMS and up to 3 years after DREAMS implementation began.
• We investigated the timing of any change in HIV incidence and whether any decline in
incidence rates accelerated during DREAMS implementation.
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(https://data.ahri.org/index.php/home). Requests
for the data from Kenya can be made to the KEMRI
Scientific and Ethics Review Unit (SERU), at
https://www.kemri.org/seru-overview or by
contacting SERU at seru@kemri.org.
Funding: The impact evaluation of DREAMS is
funded by the Bill and Melinda Gates Foundation
(Grant OPP1136774 to IB, http://www.
gatesfoundation.org). Foundation staff advised the
study team, but did not substantively affect the
study design, instruments, interpretation of data, or
decision to publish. Africa Health Research
Institute is supported by a grant from the
Wellcome Trust (082384/Z/07/Z). The AHRI
Demographic Surveillance Information System and
Population Intervention Programme is funded by
the Wellcome Trust (201433/Z/16/Z) and the South
Africa Population Research Infrastructure Network
(funded by the South African Department of
Science and Technology and hosted by the South
African Medical Research Council), with co-funding
from the Bill and Melinda Gates Foundation. In
Kenya, data were collected with funding from the
President’s Emergency Fund for AIDS Relief, under
Cooperative Agreements with the US Centers for
Disease Control and Prevention, and co-funding
from the Bill & Melinda Gates Foundation. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: AU : Anabbreviationlisthasbeencompiledforthoseusedthroughoutthetext:Pleaseverifythatallentriesarecorrect:YW, adolescent girls and young
women; aRR, age-adjusted rate ratio; ART,
antiretroviral treatment; CI, confidence interval;
DREAMS, Determined, Resilient, Empowered,
AIDS-free, Mentored, and Safe; DSS, demographic
surveillance site; ELISA, enzyme-linked
immunosorbent assay; PrEP, preexposure
prophylaxis; py, person-years; RR, rate ratio;
YWSS, young women who sell sex.
• In the first 3 years of DREAMS implementation, we did not observe an additional effect
of DREAMS on HIV incidence reductions among AGYW.
• Declines in HIV incidence began before DREAMS rollout.
What do these findings mean?
• The ongoing trend in HIV decline is most likely driven by investments in HIV testing,
treatment, and male circumcision that preceded DREAMS introduction and continued
alongside it.
• A complex, multisectoral programme like DREAMS needs time to scale up and
strengthen linkages between social, structural, and biomedical interventions before it
can yield measurable impacts on HIV incidence rates.
• With absolute levels of HIV risk remaining high for AGYW in uMkhanyakude, and rel-
ative risk higher among young females than young males in both settings, strengthening
of HIV prevention is needed to accelerate HIV incidence declines.
Introduction
Persistently high rates of HIV infection among adolescent girls and young women (AGYW)
have led to large investments in targeted HIV prevention in eastern and southern Africa. This
includes the “DREAMS Partnership” launched in 2015 by PEPFAR and private sector partners
to promote “Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe” (DREAMS)
lives among AGYW [1]. Through a combination package of 12 evidence-based interventions,
DREAMS promotes a multisectoral approach to reduce HIV incidence and the individual,
family, and community-based drivers of young women’s heightened risk. DREAMS was
launched in 2015 and subsequently rolled out in 63 districts across 10 countries in East and
Southern Africa. It was further expanded to new districts in 5 more countries in 2018, with
successive budget increases as it evolved from central funding to country budgets (for example,
US$189M for fiscal year 2020 and US$399M for 2021) [2].
A systematic review of directly observed HIV incidence estimates in the 10 DREAMS coun-
tries prior to DREAMS introduction showed that, while rates among AGYW have declined in
many settings since rollout of antiretroviral treatment (ART; between 2005 and 2015), they
remain substantially higher than those of their male peers in all settings [3]. The excessive risk
among adolescent girls relative to males exposes a gender gap, which DREAMS aimed to
address with urgency. Specifically, the aim of DREAMS was to reduce HIV incidence among
AGYW by 40% over 2 years [1].
This is an ambitious goal, and one that is challenging to evaluate, since DREAMS districts
were not selected at random but on the basis of HIV burden, and few DREAMS settings have
pre-DREAMS estimates of HIV incidence to measure change over time. Longitudinal popula-
tion-based surveillance of HIV is limited to about 10 settings in sub-Saharan Africa, and most
are not places where DREAMS has been implemented [4]. We identified 2 settings in which
historical HIV incidence data were collected in the general population prior to DREAMS
introduction and could be compared to new data collected prospectively after DREAMS
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rollout from early 2016 [5,6]. Here, we use retrospective and new data in both settings—dis-
tricts with historically high prevalence and incidence of HIV in Kenya and South Africa—to
investigate the impact of DREAMS among general populations of AGYW. We also tracked
HIV incidence rates among young men in the typical age range for sexual partners of AGYW
to understand trends in male risk and the epidemiological context for AGYW.
Methods
Data sources and collection, and study settings
As a complex, multisectoral programme addressing individual and contextual drivers of HIV
risk, DREAMS should have both direct and indirect effects on HIV transmission. The impact
of DREAMS on HIV incidence should therefore be evident at the population level. This popu-
lation-based cohort study is reported as per STROBE guidelines (S1 STROBE Checklist).
To examine population-level time trends in HIV incidence, we used data from 2 commu-
nity-wide demographic surveillance sites (DSS) in which DREAMS was implemented from
2016: uMkhanyakude, a rural district of KwaZulu-Natal in South Africa, and Gem, a sub-
county of Siaya County in western Kenya. We used seroprevalence data collected before 2016
for baseline (pre-DREAMS) measures. Serological data were collected annually since 2006 in
uMkhanyakude, and over 3 rounds during 2010 to 2014 in Gem [7,8]. In both settings, further
prospective rounds of HIV serosurveillance were conducted annually between 2016 and 2019
and used to estimate HIV incidence in that time period. The methods and settings are
described in detail elsewhere [5,7–9]. Surveillance procedures included collection of a dried
blood spot for anonymised testing in uMkhanyakude, while in Gem, home-based rapid HIV
testing was provided as a service and a self-report of HIV-positive status was also taken as evi-
dence of an individual’s HIV status.
In South Africa, where pre-DREAMS annual HIV incidence was estimated to be 6% among
15- to 24-year-old AGYW, we estimated that there would be at least 3,000 person-years (py) of
follow-up after DREAMS rollout and that study power was 95% to show a 40% reduction in
HIV incidence. In Kenya, where pre-DREAMS HIV incidence was much lower, at 0.7%
among AGYW aged 15 to 24 years, we estimated that with 9,000 py of follow-up, study power
was 70% to show a 40% reduction in HIV incidence [5]. To maximise participation of AGYW
in post-DREAMS surveys, we intensified recruitment efforts with dedicated tracking teams,
point-of-care HIV testing available to those wishing to know their HIV status, and compensa-
tion of mobile phone airtime from 2017 (in uMkhanyakude; 10 Rand (US$0.70) provided to
the 15- to 24-year-old living in the household), and greater frequency of survey rounds (in
Gem).
Statistical analysis
Analyses were restricted to residents aged 15 to 24 years who had at least 2 HIV test results,
with the first HIV-negative test before the age of 25. HIV incidence rates were calculated as the
number of seroconversions per 100 py of observation. Participants entered the analysis from
their first HIV negative test and exited with the latest of date of the last negative test or their
estimated seroconversion date, if that date was before age 25 years. Individuals whose last neg-
ative test/estimated seroconversion was after the age of 25 were censored when they turned 25.
We compared the age distribution of the eligible AGYW who did and did not contribute per-
son-years of follow-up to the HIV incidence analyses in each calendar year (those with and
without repeat HIV tests during or after the calendar year being considered).
Seroconversion dates were multiply-imputed (a minimum of 100 imputations was prespeci-
fied; 100 imputations were used in Gem and 250 in uMkhanyakude) as a fraction of the
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interval between the last negative test date and the first positive test date, assuming a uniform
distribution. This was done in order to avoid grouping (clustering) of seroconversion dates by
calendar year, which will occur with the simpler “mid-point” imputation method unless sero-
surveys are conducted annually. Some participants leave the surveillance areas for a period of
time and later return. To exclude from the analysis the infections that may have occurred out-
side the DREAMS intervention areas, we excluded seroconversions for which the imputed
seroconversion date was during a period when an individual was resident outside the area and
censored those participants (as HIV negative) on the date of out-migration before the serocon-
version [7]. Correspondingly, among individuals who remained HIV negative, we also
excluded from the analysis the person-years during which they were not resident in the DSS
area. As a sensitivity analysis, HIV incidence rates were also calculated with the inclusion of all
nonresidency periods, in which all seroconversions contributed to the numerator and all per-
son-time during periods of nonresidency contributed to the denominator.
The a priori analysis plan was to compare HIV incidence among AGYW in calendar peri-
ods after DREAMS was rolled out with the 5-year period immediately prior to rollout (2011 to
2015) [5]. The DREAMS scale-up period was monitored up to 3 years after DREAMS inter-
ventions were introduced, that is, 2016 to 2019. (DREAMS interventions were funded through
2018 in uMkhanyakude and 2019 in Gem.) In Gem, we included all the 2019 serological data
to estimate HIV incidence rates to the end of 2019. In uMkhanyakude, we used the 2019 sero-
logical data but censored the analysis at the end of 2018, because the 2019 surveillance data on
residency were incomplete and because DREAMS investments stopped in this setting by late
2018.
Poisson regression was used to estimate rate ratios (RRs) and 95% confidence intervals
(CIs) for the effect of calendar period on HIV incidence, overall and separately by age group
(age 15 to 19 years and 20 to 24 years). In uMkhanyakude, where serological surveys were con-
ducted annually, we also estimated HIV incidence for every calendar year and used RRs to
compare rates from 1 year to the next to identify the timing of any change in trend. Informed
by these time trends in annual incidence rates, we created and compared a posteriori calendar
periods for evidence of additional change in HIV incidence rates during the DREAMS scale-
up period. This approach fits within the framework of an interrupted time series analysis as it
identifies a key time point, and then asks whether a time trend alters the trajectory (slope) after
that time point [10]. In Gem, where pre-DREAMS surveys were less frequent, the 2010 to 2015
baseline period was split into 2 separate periods (2010 to 2012 and 2013 to 2015), a posteriori,
to assess the timing of changes in HIV incidence rates more precisely, controlling for age
group.
HIV incidence trends were also estimated for young men characterised in earlier research
to be in the typical age range for male sexual partners of AGYW: 20 to 29 years in uMkhanya-
kude and 20 to 34 years in Gem [11]. We used the same analytical methods to estimate HIV
incidence by calendar time period, as described above for AGYW, censoring data at the esti-
mated time of seroconversion or by the age of 29 in uMkhanyakude and 34 years in Gem.
Laboratory methods
In uMkhanyakude, South Africa, dried blood spots were tested for HIV antibody using an
enzyme-linked immunosorbent assay (ELISA). From 2006 to 2008, Vironostika HIV Uni-
Form II Ag/Ab (bioMérieuxAU : PleaseprovidemanufacturerlocationdetailsforbioM�erieuxandBio   RadinthesentenceFrom2006to2008;VironostikaHIVUni   FormIIAg:::) was us d, with th GAC ELISA (Bio-Rad) as a c nfirmatory test.
From 2008 to 2019, the SD HIV 1/2 ELISA (V3) was used. In Gem, Kenya, rapid HIV testing
followed the national testing algorithm of the Kenyan Ministry of Health. Samples were tested
with Determine (AlereAU : PleaseprovidemanufacturerlocationdetailsforAlere; StandardDiagnostics;Premier; andTrinityinthesentenceSamplesweretestedwithDetermineðAlereÞ;withpositivetestsconfirmedwith:::), with positive tests co firmed with SD Bioline HIV-1/2 3.0 i 2011
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and 2012 (Standard Diagnostics) and First Response (Premier) in 2016, and Uni-gold (Trinity)
used as a referee test. In both settings, the DSS resident identification number was recorded
and used for linkage of individuals’ HIV test results and data from questionnaires.
Patient and public involvement, and ethics approvals
In both settings, studies are presented to the Community Advisory Board for their input and
permission before submitting for ethics clearance. The study protocol and tools were approved
by ethics committees at the London School of Hygiene and Tropical Medicine and Liverpool
School of Tropical Medicine in the United Kingdom; Kenya Medical Research Institute in
Kenya; and University of KwaZulu-Natal in South Africa. Participants provided informed,
written consent to participate as did parents/guardians of legal minors under age 18 years.
Results
In uMkhanyakude, from 2006 to 2019, between 5,000 and 6,000 AGYW aged 15 to 24 years
were eligible for the serological survey each year, and an average of 85% were contacted (range
76% to 96%) (Table 1). Consent rates were under 50% from 2006 to 2014, after which annual
participation rates (among those contacted) rose to around 60%, with intensified recruitment
and tracking of AGYW from 2017. Around 3,000 AGYW were eligible for the HIV incidence
cohort each year (first observed as HIV negative before age 25, and without evidence of sero-
conversion before that year), of whom an average of 75% had a repeat HIV test in that year or
a later one and so contributed person-time to the analysis. Total follow-up time was 26,393 py:
14,184 py among 15- to 19-year-olds; and 12,209 py among 20- to 24-year-olds. For each cal-
endar year of follow-up, AGYW who contributed person-years to the analysis were on average
Table 1. Testing participation in HIV serosurveys among AGYW and contribution to HIV incidence cohort in uMkhanyakude, South Africa.
Year HIV survey HIV incidence cohort
Eligible1 Contacted (% of eligible)1 Consented (% of contacted)1 Eligible (aged <25 years)2 Repeat testers3
2006 5,822 5,558 (95.5%) 2,578 (46.4%) 3,246 2,700 (83.2%)
2007 6,033 5,396 (89.4%) 2,165 (40.1%) 3,268 2,595 (79.4%)
2008 5,937 5,443 (91.7%) 2,057 (37.8%) 3,103 2,569 (82.8%)
2009 4,977 4,449 (89.4%) 1,623 (36.5%) 2,763 2,232 (80.8%)
2010 5,743 4,768 (83.0%) 2,154 (45.2%) 3,018 2,383 (79.0%)
2011 4,959 4,278 (86.3%) 1,868 (43.7%) 2,791 2,214 (79.3%)
2012 5,406 4,207 (77.8%) 1,582 (37.6%) 2,757 2,070 (75.1%)
2013 5,534 4,428 (80.0%) 2,082 (47.0%) 3,000 2,248 (74.9%)
2014 5,390 4,265 (79.1%) 1,878 (44.0%) 2,987 2,264 (75.8%)
2015 5,039 4,367 (86.7%) 2,613 (59.8%) 3,087 2,426 (78.6%)
2016 5,249 4,509 (85.9%) 3,020 (67.0%) 3,395 2,525 (74.4%)
2017 5,220 4,404 (84.4%) 2,088 (47.4%) 3,180 2,194 (69.0%)
2018 5,029 3,834 (76.2%) 2,345 (61.2%) 3,153 1,809 (57.4%)
1Among AGYW aged 15–24 years.
2Cumulative number of AGYW who first tested HIV negative when aged <25 years are eligible for entry into the HIV incidence cohort and are still aged <25 years.
3Number of eligible HIV negative AGYW who had a repeat test and contributed person-time to the incidence analysis during each calendar period. For example, if an
AGYW first tests HIV negative in 2006 and has a second HIV-negative test in 2010, she contributes person time to 2006, 2007, 2008, 2009, and 2010. Individuals leave
the AGYW incidence cohort at the earliest estimate of seroconversion or reaching the age of 25.
AGYWAU : AbbreviationlistshavebeencompiledforthoseusedinTables1   6:Pleaseverifythatallentriesarecorrect:, adolescent girls and young wom .
https://doi.org/10.1371/journal.pmed.1003837.t001
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slightly older than those who did not contribute; the differences in mean age were small (<1
year) and changed little over the study period (S1 Table).
In Gem, 2 rounds of serological surveys were conducted before DREAMS introduction,
between 2010 and 2015, and annual rounds were subsequently conducted between 2016 and
2019 (Table 2). Between 8,515 and 11,428 AGYW aged 15 to 24 years were eligible each round,
and an average of 34% were contacted and offered an HIV test. Consent rates ranged between
84% to 99%. Of those eligible for the HIV incidence cohort each year, between 40% and 60%
had a repeat test and contributed person-time to the HIV incidence analysis. AGYW with
repeat HIV test results contributed a total of 10,382 py to the HIV incidence cohort (6,102 py
among 15- to 19-year-olds; 4,279 py among 20- to 24-year-olds), with 2,325 py of follow-up
during the DREAMS implementation period 2016 to 2019.
HIV incidence trends among AGYW, by calendar period and round
In the calendar period since DREAMS implementation began in uMkhanyakude (2016 to
2018), rates of HIV incidence among AGYW were lower, overall and in both age groups, com-
pared to the 5-year period immediately prior to DREAMS. Rates were lower by 38% among
15- to 19-year-olds in that time frame (4.5 cases per 100 py in 2011 to 2015 as compared with
2.8 per 100 py in 2016 to 2018 [age-adjusted RR (aRR) = 0.62; 95% CI 0.48 to 0.82]), and by
18% among 20- to 24-year-olds (7.1 per 100 py as compared with 5.8% [aRR = 0.82; 95% CI
0.65 to 1.04]) (Table 3). Estimates of HIV incidence calculated for each individual year indicate
that annual declines in HIV incidence began before DREAMS introduction in 2016 (Table 4,
Table 2. Testing participation in HIV serosurveys among AGYW and contribution to HIV incidence cohort in uMkhanyakude, South Africa (A) and Gem, Kenya
(B).
Round HIV survey HIV incidence cohort
Eligible for HIV
survey1































9,920 3,438 (34.7%) 2,900 (84.4%) 5,890 41 (0.7%)
1AGYW aged 15–24 years who were resident in a randomly selected study compound during the serosurvey round.
2Consented to participate (to provide a blood sample for HIV testing or self-reported as HIV+).
3Cumulative number of AGYW who first tested HIV negative when aged <25 and are eligible for entry into the HIV incidence cohort and are still aged <25 years.
4Number of eligible HIV negative AGYW who had a repeat test and contributed person-time to the HIV incidence analysis during each calendar period.
�Those who were NOT offered and those who did NOT consent were not collected during the 2017 survey round.
AGYW, adolescent girls and young women.
https://doi.org/10.1371/journal.pmed.1003837.t002
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Fig 1). Rates among 15- to 19-year-olds were highest in 2012, after which they subsequently
declined each year through 2017, with the difference compared to 2011 widening with each
successive year. Among 20- to 24-year-olds, declines began later, from 7.8 cases per 100 py in
2014 followed by annual reductions thereafter to 5.2 per 100 py in 2018.
In comparisons of a posteriori calendar periods informed by the observed trends in annual
incidence rates, among the younger cohort, we found evidence that HIV incidence fell during
2013 to 2015 by around 13% per year (aRR = 0.87; 95% CI 0.76 to 0.99, p = 0.03) (Table 5).
During the 3 years, 2016 to 2018, this rate of reduction continued, but there was no evidence
of additional change (aRR for additional annual rate of change during 2016 to 2018 = 1.06;
95% CI 0.81 to 1.39). Among the older cohort, there was no evidence of decline between 2006
and 2014, a suggestion of a decline of around 9% comparing 2015 with 2014 (aRR = 0.91, 95%
CI [0.63 to 1.31]), and no evidence of more rapid decline during 2016 to 2018 (aRR for addi-
tional annual rate of change during 2016 to 2018 = 1.02, 95% CI 0.63 to 1.64). Combining the
years 2015 to 2018, there was weak evidence that HIV incidence fell by around 8% per year
over this 4-year period (aRR = 0.92; 95% CI 0.84 to 1.01; p = 0.07).
Table 3. Incidence of HIV infection among AGYW, by age and DREAMS implementation period in uMkhanyakude, South Africa and Gem, Kenya.
Age group Calendar period New HIV infections Person-years Incidence rate/100 py aRR (95% CI)1
uMkhanyakude, South Africa
15–19 years 2006–2010 269 5,663 4.75 (4.13–5.46) 1.04 (0.85–1.28)
2011–2015 227 4,992 4.54 (3.93–5.25) 1
2016–2018 98 3,529 2.78 (2.24–3.46) 0.62 (0.48–0.82)
20–24 years 2006–2010 365 4,866 7.50 (6.64–8.47) 1.06 (0.89–1.27)
2011–2015 336 4,743 7.08 (6.23–8.04) 1
2016–2018 151 2,600 5.80 (4.81–7.00) 0.82 (0.65–1.04)
15–24 years 2006–2010 634 10,529 6.02 (5.51–6.58) 1.06 (0.92–1.21)
2011–2015 563 9,736 5.78 (5.27–6.34) 1
2016–2018 249 6,130 4.07 (3.54–4.67) 0.74 (0.62–0.87)
Gem, Kenya
- Comparison of 2 calendar periods (a priori analysis)
15–19 years 2010–2015 30 4,866 0.62 (0.40–0.94) 1
2016–2019 6 1,236 0.49 (0.16–1.50) 0.79 (0.24–2.63)
20–24 years 2010–2015 31 3,191 0.97 (0.63–1.50) 1
2016–2019 7 1,088 0.64 (0.28–1.49) 0.66 (0.26–1.70)
15–24 years 2010–2015 61 8,057 0.76 (0.55–1.04) 1
2016–2019 13 2,325 0.56 (0.28–1.11) 0.74 (0.36–1.53)
- Comparison of 3 calendar periods (a posteriori analysis)
15–19 years 2010–2012 20 2,171 0.92 (0.57–1.49) 2.48 (1.16–5.31)
2013–2015 10 2,695 0.37 (1.90–7.30) 1
2016–2019 6 1,236 0.49 (0.16–1.50) 1.31 (0.35–4.89)
20–24 years 2010–2012 16 1,588 1.01 (0.60–1.69) 1.08 (0.53–2.18)
2013–2015 15 1,603 0.94 (0.52–1.70) 1
2016–2019 7 1,088 0.64 (0.28–1.49) 0.69 (0.53–2.18)
15–24 years 2010–2012 36 3,759 0.96 (0.67–1.36) 1.65 (0.99–2.75)
2013–2015 25 4,298 0.58 (0.37–0.92) 1
2016–2019 13 2,325 0.56 (0.28–1.11) 0.96 (0.43–2.14)
1Adjusted for current age.
AGYW, adolescent girls and young women; aRR, age-adjusted rate ratio; CI, confidence interval; py, person-years.
https://doi.org/10.1371/journal.pmed.1003837.t003
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In Gem, HIV incidence estimates during the DREAMS implementation period (2016 to
2019) were lower than those observed in the 5-year period prior to DREAMS (2010 to 2015),
but there was considerable statistical uncertainty around the estimates (Table 3). For example,
among 15- to 24-year-olds overall, HIV incidence was estimated as 0.56 cases per 100 py (95%
CI 0.28 to 1.11) since DREAMS began, as compared with 0.76% (95% CI 0.55 to 1.04) in the
baseline period (aRR = 0.74, 95% CI 0.35 to 1.53).
The incidence rate in Gem was highest in the earlier surveillance period (2010 to 2012) at
0.96% (95% CI 0.67 to 1.36) and declined to 0.58% (95% CI 0.37 to 0.92) by 2013 to 2015
(aRR = 1.65, 95% CI 0.99 to 2.75) (Table 3). This difference was driven by a reduction in rates
among the younger cohort (15- to 19-year-olds). In a posteriori analysis, defining the baseline
period as 2013 to 2015, we found no evidence of a reduction among 15- to 24-year-olds overall
since DREAMS rollout in Gem (aRR = 0.96, 95% CI 0.43 to 2.14) (Table 3, Fig 2). Compared
to 2013 to 2015, there was no evidence of a decline in HIV incidence during the DREAMS
implementation period in the 15- to 19-year-olds (aRR 1.31, 95% CI 0.35 to 4.89) or among
the 20- to 24-year-olds (aRR = 0.69, 95% CI 0.53 to 2.18).
Sensitivity analyses estimating HIV incidence regardless of gaps in residency (that is,
including seroconversions and follow-up time spent outside of the geographic surveillance
area of Gem) enabled the inclusion of substantially more person-years of follow-up post-
Table 4. Incidence of HIV infection among AGYW, by age and individual year in uMkhanyakude (2006–2018).
Age group Year New HIV infections Person-years Incidence rate/100 py RR (95% CI) (reference year 2011)
15–19 years 2006 61 1,314 4.60 (3.30–6.42) 0.93 (0.56–1.53)
2007 57 1,252 4.53 (3.25–6.32) 0.92 (0.55–1.53)
2008 55 1,197 4.55 (3.23–6.41) 0.92 (0.55–1.54)
2009 52 1,006 5.14 (3.62–7.32) 1.04 (0.62–1.75)
2010 44 893 4.91 (3.32–7.27) 0.99 (0.56–1.76)
2011 47 951 4.95 (3.38–7.23) 1
2012 47 855 5.45 (3.77–7.87) 1.10 (0.63–1.92)
2013 48 969 4.96 (3.45–7.14) 1.00 (0.58–1.73)
2014 44 1,073 4.08 (2.77–6.02) 0.83 (0.48–1.41)
2015 40 1,145 3.48 (2.37–5.11) 0.70 (0.40–1.22)
2016 35 1,240 2.80 (1.84–4.24) 0.57 (0.32–0.99)
2017 30 1,211 2.48 (1.56–3.94) 0.50 (0.28–0.90)
2018 33 1,078 3.04 (2.01–4.59) 0.61 (0.35–1.07)
20–24 years 2006 70 880 7.96 (5.92–10.72) 1.20 (0.77–1.88)
2007 71 945 7.42 (5.44–10.12) 1.12 (0.71–1.77)
2008 74 1,001 7.33 (5.45–9.84) 1.11 (0.70–1.74)
2009 76 1,023 7.35 (5.46–9.90) 1.11 (0.70–1.76)
2010 75 1,017 7.34 (5.44–9.90) 1.11 (0.69–1.77)
2011 66 994 6.62 (4.74–9.25) 1
2012 69 961 7.18 (5.31–9.70) 1.08 (0.68–1.74)
2013 67 942 7.04 (5.13–9.66) 1.06 (0.67–1.69)
2014 73 934 7.74 (5.79–10.36) 1.17 (0.75–1.82)
2015 61 911 6.67 (4.86–9.16) 1.01 (0.63–1.61)
2016 54 854 6.27 (4.38–8.95) 0.95 (0.58–1.54)
2017 52 889 5.83 (4.09–8.30) 0.88 (0.54–1.43)
2018 45 858 5.22 (3.59–7.60) 0.79 (0.48–1.31)
AGYW, adolescent girls and young women; CI, confidence interval; py, person-years; RR, rate ratio.
https://doi.org/10.1371/journal.pmed.1003837.t004
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DREAMS introduction in Gem (with a total of 8,456 py among 15- to 24-year-old women; S2
Table). This analysis generated lower estimates of HIV incidence across age groups and time
but yielded similar time trends. That is, declines in HIV incidence among the younger cohort
were seen before DREAMS implementation (between 2010 and 2012 and 2013 and 2015) but
not thereafter. Among the older cohort, there was no evidence of decline before DREAMS,
and a 25% reduction observed during DREAMS implementation that did not achieve statisti-
cal significance (aRR = 0.75, 95% CI 0.43 to 1.29).
Fig 1. HIV incidence rates over time among AGYW with 95% CIs, in uMkhanyakude, South Africa. AGYWAU : AbbreviationlistshavebeencompiledforthoseusedinFigs1   4:Pleaseverifythatallentriesarecorrect:,
adolescent girls and young women; CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003837.g001
Table 5. Trends in HIV incidence among AGYW, by age and a posteriori calendar time periods in uMkhanya-
kude, South Africa.
Age group Comparison� Age-adjusted linear RR (95% CI) P value
15–19 years Change in 2011–2012 vs 2006–2010 1.12 (0.86–1.45) 0.41
Trend from 2013 to 2015 0.87 (0.76–0.99) 0.03
Additional change from 2016 to 2018 1.06 (0.81–1.39) 0.65
20–24 years Trend from 2006 to 2010 0.97 (0.89–1.05) 0.48
Trend from 2011 to 2014 1.01 (0.93–1.10) 0.74
Change in 2015 vs 2014 0.91 (0.63–1.31) 0.61
Additional change from 2016 to 2018 1.02 (0.63–1.64) 0.94
20–24 years Trend from 2006 to 2010 0.97 (0.90–1.05) 0.48
Trend from 2011 to 2014 1.01 (0.94–1.09) 0.73
Trend from 2015 to 2018 0.92 (0.84–1.01) 0.07
�Time periods are informed by the year in which HIV incidence first began to decline, for 15- to 19-year-olds and
20- to 24-year-olds, based on Table 4.
AGYW, adolescent girls and young women; CI, confidence interval; py, person-years; RR, rate ratio.
https://doi.org/10.1371/journal.pmed.1003837.t005
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HIV incidence trends among young men
Among young men aged 20 to 29 years in uMkhanyakude, lower rates of HIV incidence were
observed in the DREAMS implementation period: 1.1% in 2016 to 2018 as compared with
2.6% in the preceding 5 years among those aged 20 to 24 (aRR = 0.44, 95% CI 0.26 to 0.77);
and 2.4% versus 4.1% among men aged 25 to 29 years (aRR = 0.58, 95% CI 0.34 to 0.99)
(Table 6). As with AGYW in this setting, estimates calculated for each annual round show that
declines began before DREAMS introduction, from about 2012 when incidence peaked at
3.3% among 20- to 24-year-old men and from 2013 when rates among 25- to 29-year-olds
were highest at 4.7%. There were steady declines each year thereafter through 2018, in both
age groups (S3 Table, Fig 3).
Among young men aged 20 to 34 years in Gem, HIV incidence rates were lower with each
successive calendar period, with uncertainty around the estimates (Table 6, Fig 4). In sensitiv-
ity analyses estimating HIV incidence without residency gaps and thus including substantially
more person-time, there was no evidence of change in HIV incidence over time (aRR = 0.94,
95% CI 0.32 to 2.80) (S4 Table).
Discussion
We observed large declines in HIV incidence among AGYW in both settings over the duration
of this study. With data from HIV surveillance rounds conducted between 2010 and 2015 and
prospective serological surveys conducted in the first 3 years of DREAMS implementation, we
found that infection rates were lower in the DREAMS implementation period than the preced-
ing 5-year calendar period. However, in more detailed analysis of trends, with annual
Fig 2. HIV incidence rates over time among AGYW with 95% CIs, in Gem, Kenya. AGYW, adolescent girls and
young women; CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003837.g002
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surveillance data in uMkhanyakude and comparison of a posteriori calendar periods in both
settings, we conclude that declines began several years before DREAMS introduction and con-
tinued, but did not accelerate, during DREAMS first 3 years of implementation.
Among young women aged 20 to 24 years in Gem, HIV incidence remained stable prior to
DREAMS introduction (at approximately 1% between 2010 and 2015) and declined by 31%
Table 6. Incidence of HIV infection among young men, by age and DREAMS scale-up period in uMkhanyakude, South Africa and Gem, Kenya.
Age group Calendar period New HIV infections Person-years Incidence rate/100 py aRR (95% CI)1
uMkhanyakude, South Africa
20–24 years 2006–2010 119 3,901 3.04 (2.43–3.79) 1.19 (0.86–1.65)
2011–2015 99 3,865 2.56 (2.03–3.22) 1
2016–2018 24 2,081 1.13 (0.70–1.83) 0.44 (0.26–0.77)
25–29 years 2006–2010 67 1,507 4.41 (3.28–5.92) 1.08 (0.73–1.60)
2011–2015 97 2,375 4.07 (3.18–5.20) 1
2016–2018 30 1,262 2.36 (1.49–3.73) 0.58 (0.34–0.99)
Gem, Kenya
20–24 years 2010–2012 10 1,421 0.70 (0.38–1.31) 2.30 (0.73–7.26)
2013–2015 6 1,957 0.31 (0.11–0.86) 1
2016–2019 3 1,462 0.21 (0.07–0.64) 0.67 (0.14–3.10)
25–34 years 2010–2012 21 1,940 1.08 (0.71–1.66) 1.54 (0.79–2.99)
2013–2015 16 2,277 0.70 (0.41–1.21) 1
2016–2019 8 1,376 0.58 (0.29–1.16) 0.83 (0.38–1.80)
1Adjusted for current age.
aRR, age-adjusted rate ratio; CI, confidence interval; py, person-years.
https://doi.org/10.1371/journal.pmed.1003837.t006
Fig 3. HIV incidence rates over time among young men with 95% CIs, in uMkhanyakude, South Africa. CI,
confidence interval.
https://doi.org/10.1371/journal.pmed.1003837.g003
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during the DREAMS implementation period 2016 to 2019; however, statistical evidence (a
wide confidence interval, indicating that the data were compatible with an RR of 1), shows that
this may be a chance finding. Despite this uncertainty, it is plausible that DREAMS reduced
HIV risk among young women in Gem, where the same evaluation found that DREAMS had a
high reach and good layering of multiple interventions that intensified with time [12]. As part
of the same evaluation, we established and followed nested closed cohorts of AGYW, randomly
sampled from the population platform and followed over 2 years, to measure DREAMS cover-
age and causal impacts on individual-level outcomes [5,12]. In Gem, we observed a reduction
in lifetime number of sexual partners and condomless sex among DREAMS beneficiaries com-
pared with nonbeneficiaries, and evidence of other changes along a causal pathway between
DREAMS and HIV risk, such as knowledge of HIV status and social support [13–15]. There
were weaknesses, however, in the HIV “prevention cascade”—with poor links from high HIV
testing to prevention services like preexposure prophylaxis (PrEP) and condom promotion,
and uptake of both remained low by 2019. With more time and availability of PrEP, these link-
ages could be strengthened to improve young women’s prevention choices in this setting
[6,14,16].
The absence of an impact on HIV incidence in uMkhanyakude is consistent with other evi-
dence emerging in that setting, including no evidence of DREAMS impact on the high rates of
HSV-2 among AGYW [17]. Individual-level analyses comparing outcomes among DREAMS
beneficiaries and nonbeneficiaries suggest that DREAMS did not directly affect behavioural
drivers of sexual risk in this setting. Like in Gem, reach of DREAMS interventions from 2016
was high among the general population of AGYW in uMkhanyakude, but investment ceased
by 2018, before PrEP for HIV was integrated within DREAMS and arguably before normative
changes could occur [12,18,19]. Also, deeper engagement with young women and the wider
Fig 4. HIV incidence rates over time among young men with 95% CIs, in Gem, Kenya. CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003837.g004
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community could have strengthened the acceptability, innovation, and adaptation of
DREAMS interventions to the needs and challenges of this particular context [18]. The HIV
declines may be due to time trends in population- and partner-level risks, which began before
DREAMS and continued afterwards. For example, wide-scale rollout of HIV testing, treat-
ment, and voluntary male circumcision services have been shown to increase coverage against
90:90:90 targets among young men, thus reducing levels of untreated HIV infection among
men in the typical age bracket for sexual partners of AGYW [20,21]. Modelling and phyloge-
netic studies suggest that preventing transmission from one young man can avert infections in
up to 4 young women [22,23]. The significant reductions we observed in HIV incidence
among young men since 2012 to 2013, together with increases in reported condom use, cir-
cumcision, and HIV treatment uptake, would have altered the context of HIV risk for AGYW
prior to DREAMS investments in uMkhanyakude [24].
These data contribute to growing evidence that HIV incidence has reduced for AGYW
across east and southern Africa, in the years leading up to 2020, though they remain at very
high risk relative to men and other age groups [3]. In both study settings, HIV incidence
declined first among the younger cohort (circa 2013 for adolescent girls aged 15 to 19 years)
and later among young women aged 20 to 24 years—the age when HIV incidence peaked for
women. Declines have also taken longer to occur in very high prevalence settings like uMkha-
nyakude, compared to lower-prevalence settings [25]. Despite the encouraging declines
observed with time, the most recent estimates remain very high at>5% incidence among
women aged 20 to 24 years in uMkhanyakude, about 5 times higher than men of the same age
(approximately 1% in 2017). The estimated 3% incidence among girls aged 15 to 19 years in
2018 shows that absolute levels of risk are still high from an early age, despite steady reductions
since 2012. High rates have also been reported in other settings of KwaZulu Natal, for example,
in Durban, where the HIV epidemic has been described as “continuous, unrelenting, hyper”
[26].
In such settings, in which HIV and other STI risks (and HIV/STI coinfection) remain high,
the indirect effects of ART availability and male partner risk are slow to change the context of
risk for young women and more must be done to protect young women from infection. Even
community-randomised trials of population-wide universal test and treat interventions,
offered intensively in high-burden settings, have yielded modest reductions in HIV incidence
over a 3- to 4-year time frame, of the order of 20% to 30% [20,27]. DREAMS sought to address
the drivers of AGYW risk directly and indirectly, comprehensively, and urgently, but invest-
ments in uMkhanyakude stopped in 2018, before the programme had an opportunity to
embed in a high-priority setting [18,28]. In this setting, and in a related impact evaluation in
Zimbabwe, very low proportions of young women who sell sex (YWSS) were reached with
DREAMS interventions, limiting plausibility of its impact among the highest-risk women
[19,29]. Research to understand the profile of AGYW who were reached by DREAMS in the
Kenyan and South African study settings revealed that those who may be at most immediate
sexual risk (for example, sexually active, ever pregnant) were less likely to be invited to
DREAMS, although this improved with time [12]. DREAMS set a very ambitious target in a
short time frame of 2 years. With more time to scale up and adapt interventions to reach those
who need them most, by addressing stigma towards YWSS and training implementers be
more inclusive, integrated packages that blend biomedical (including PrEP) and structural
interventions (to boost education, employment, and empowerment) can be crucial to reduce
young women’s risk. Meanwhile, efforts to reduce male partner risk should also be intensified
even in contexts of high treatment coverage, by targeting young men for earlier HIV diagnosis,
treatment, and VMMC to avoid transmission in early stages of infection [20,23,30].
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Strengths and limitations
A strength of the study lies in the directly observed measure of HIV incidence, at a representa-
tive, population level, with frequent repeat measures of HIV status. Historical data provided
robust pre-DREAMS measures, and frequent rounds of serological surveys before and after
the introduction of DREAMS enabled us to observe trends and identify the timing at which
declines began, in relation to DREAMS rollout. DREAMS sought to scale up to district level,
and there are very few DREAMS districts with historical HIV surveillance to serve as a baseline
for evaluation of DREAMS and track incidence trends in detail. Other evaluations of
DREAMS lack biological endpoints or rely on HIV test data from antenatal care clients (thus
missing those who are not pregnant or do not seek care) and measure HIV-positive diagnoses
at district level as the primary outcome [1]. This can be a reflection of HIV testing reach and
positivity rates, rather than a measure of new HIV infections and HIV risk. DREAMS is a very
large investment, and direct measurement of HIV incidence at the population level in some
settings is warranted to verify if DREAMS achieved its target for HIV incidence reduction.
Capitalising on existing research platforms was an efficient way to evaluate this aim.
With large annual survey rounds and high HIV incidence in South Africa, there was suffi-
cient study power to detect a smaller difference than the ambitious DREAMS target of a 40%
reduction in HIV incidence, and we found evidence of an average reduction of approximately
25% across the 3 years of DREAMS rollout (2016 to 2018) compared with the years immedi-
ately before. (This corresponds to the observed annual reduction (relative to the previous year)
of approximately 10% per year.) Although this rate of decline preceded DREAMS introduc-
tion, it is encouraging that it continued and did not slow. In Gem, we had sufficient power to
detect a minimum change of 40% among 15- to 24-year-old AGYW, in the sensitivity analyses
which included residency gaps in the person-years of follow-up and which showed similar
results to the original analysis. More person-years of follow-up are needed to provide statistical
evidence of a reduction that is less than 40% in this setting, especially the observed 31% reduc-
tion in one subgroup: the older cohort of 20- to 24-year-old women.
We proposed a rigorous design in the absence of randomisation. A cluster-randomised trial
design was not possible because the priority of the DREAMS Partnership was for rapid rollout
of DREAMS investments to geographic areas chosen for their high HIV prevalence, rather
than to a randomly selected sample of areas. The absence of a counterfactual (of what would
have happened over time in the absence of DREAMS) limits our ability to attribute change to
DREAMS or rule out the influence of other interventions and secular trends. It is possible that
the sustained decline observed in HIV incidence was due to DREAMS and would not have
occurred otherwise. It is arguably more difficult to demonstrate an impact of DREAMS against
a background of HIV incidence decline than to do so against a background of stable HIV inci-
dence. There was no evidence that DREAMS reversed the encouraging declines, indicating
that it did not disrupt positive trends.
With annual rounds of serosurveillance in South Africa, participation rates in any particular
year were relatively low (for example, due to absence from home or study fatigue); however,
cumulative rates of participation among eligible individuals increased with time and recruit-
ment opportunities. Overall, about 75% of eligible AGYW contributed person-time during fol-
low-up, which is relatively high for population-based surveillance. In Kenya, the proportion
contacted and offered an HIV test was lower, since surveys were done primarily as service pro-
vision (home-based testing to link HIV-infected individuals to care), and those with a known
HIV positive status did not require a new test. However, the approach to reaching people has
remained consistent over time, and the population reached is comparable over time [31]. With
less frequent serosurveillance in this setting compared to South Africa, and high mobility
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among young adults, there was less opportunity for repeat testing, and, thus, the proportion
who contributed person-time to our analyses was lower. While repeated HIV testing via popu-
lation-based surveillance is considered by many to be the gold standard for measuring HIV
incidence trends, such studies are challenged by the systematic exclusion of some subgroups
due to noncontact or refusal [32]. The consequence is most likely that absolute levels of HIV
incidence in this and other studies may be underestimated, because more mobile groups are
disproportionately missed [33]. However, as noted above, in uMkhanyakude, a high propor-
tion of eligible AGYW contributed follow-up time to the analysis, and the proportion contrib-
uting to the analysis was fairly consistent over the study period. Also, in previous analyses of
participation dynamics in the South Africa surveillance site, the HIV testing rate did not differ
substantially by age or sex over time, and the demographic composition (age and sex) of the
HIV–negative testers and the HIV cohort remained stable over time [32,34].
Our method of estimating HIV incidence may underestimate HIV incidence rates, if young
people are less able to meet the need to have tested twice (for example, if they miss a survey
round because they are too young to participate). This is more likely to be the case in Gem
than in uMkhanyakude where there were more frequent opportunities to test. While participa-
tion rates were lower in uMkhanyakude, previous research from this setting suggests that par-
ticipation bias can reduce the accuracy with which seroconversions can be dated,
undermining validity, but does not introduce a systematic bias. Longer-term follow-up, with
the benefit of additional serological data collected after 2019, would increase the accuracy of
the “tail-end” of our estimates, since people did not participate in every HIV survey round.
Conclusions
HIV risk has been persistently high among AGYW in east and southern Africa, and these data
offer detailed and encouraging evidence of recent and large declines in 2 settings with an his-
torically high burden of HIV. Frequent rounds of directly observed HIV incidence reveal that
the declines predated DREAMS introduction in both settings and thus cannot be attributed to
the initial years of DREAMS interventions. They are most likely driven by improvements in
HIV services and treatment of HIV–positive individuals, and voluntary male medical circum-
cision, validating the importance of sustained investment in early diagnosis, treatment, and
prevention, for young adult men as well as women. Nevertheless, young women’s risk remains
high—in absolute levels in South Africa and relative to men of the same age in both settings.
HIV incidence reductions are not on track for epidemic control or global targets to end HIV/
AIDS as a public health threat by 2030. A complex intervention like DREAMS needs time to
embed and strengthen its impact. Time is also needed to measure the true impact of DREAMS
as younger adolescent girls age into sexual activity and higher-risk age brackets. Sustained
commitment to promoting gender equity through programmes like DREAMS—which offer
structural, social, and biomedical support to young women—are needed more than ever as the
global COVID-19 pandemic threatens progress in the related goals of HIV prevention and sus-
tainable development.
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